Jimena Davis, Ph.D.

Senior Scientist I

Jimena joined MetrumRG in June 2023 as a Senior Scientist I. She earned her PhD in Applied and Computational Mathematics from North Carolina State University. She brings with her over 15 years of mathematical modeling and computational biology experience. Jimena spent 4 years at the US EPA as a Mathematical Statistician focused on uncertainty quantification of linked exposure-to-effects models for human health risk assessments. She then applied her mathematical modeling skills in various roles at Syngenta, including modeling biological pathways to support gene candidate discovery for plant traits and breeding in various crops. Jimena enjoys modeling complex biological systems to tackle challenges that humans face, and she’s looking forward to collaborating on solutions that will inform biomedical decisions in drug development programs.

 

 

Recent publications by this scientist

A Quantitative Systems Pharmacology Platform for Atopic Dermatitis and Asthma: One Immune Cascade Calibrated to Four Biologics

October 19, 2026

Timothy Knab¹, Cole Zmurchok¹, Jimena Davis¹, Dan Kirouac¹, Richard Allen², Cody Herron²
¹Metrum Research Group, Boston, MA, USA; ²Pfizer Inc., Cambridge, MA, USA

Submitted to the 2026 American Conference on Pharmacometrics (ACoP 2026), an International Conference on Pharmacometrics in the US (ICoP – US).

Atopic dermatitis (AD) and asthma share a type-2 immune axis and the same biologics: dupilumab (anti-IL-4Rα), lebrikizumab (anti-IL-13) and tezepelumab (anti-TSLP), with mepolizumab (anti-IL-5) in asthma. Published QSP models describe each disease on its own. The objectives were to build one reaction network in which the same immune cascade, placed in skin or
airway, gives AD or asthma, and calibrate it to biologic responses in both, as well as use it to compare a combination across indications and asthma phenotypes, and to rank untested targets.

Download PDF

A Modular PBPK-QSP Platform in Julia for Optimizing the Therapeutic Window of Antibody-Drug Conjugates: ADC In Silico Design Engine (AIDE)

October 19, 2026

Yuezhe Li, Jimena Davis, Timothy Knab, Cole Zmurchok, and Daniel C. Kirouac

Submitted to the 2026 American Conference on Pharmacometrics (ACoP 2026), an International Conference on Pharmacometrics in the US (ICoP – US).

Antibody-drug conjugates (ADCs) are a rapidly evolving class of oncology therapeutics designed to expand the therapeutic index of potent cytotoxic payloads by leveraging the specificity of monoclonal antibodies. Despite clinical successes, many ADC candidates fail in late-stage development due to dose-limiting toxicities or insufficient efficacy. To support preclinical evaluation and de-risk ADC development, a modular, customizable PBPK-QSP platform using the open-source Julia package ModelingToolkit.jl was developed. This platform integrates a whole-body PBPK submodel to characterize ADC and payload biodistribution with a QSP submodel designed to predict both potential off-target toxicities and anti-tumor efficacy.

Download PDF

QSP Modeling of Loncastuximab Tesirine-lpyl Combined with T Cell-Dependent Bispecific Antibodies Bridges Knowledge and Dose Regimen Strategy

June 13, 2025

Presented at ASCPT Annual Meeting 2025. The virtual population-based lymphoma QSP model enabled systematic exploration of alternate drug combinations, dosing schemes, clinical covariates and resultant effect on anti-tumor activity in silico. The results of the LOTIS-7 study (NCT04970901), a platform study evaluating loncastuximab tesirine in combination with glofitamab, will soon be available to assess the accuracy of the model predictions.

Download PDF